BioFocus has announced that it has extended its collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.
Based on the success of the project to date, BioFocus will continue the optimization of agents for disease specific biomarkers.
“We have worked with The Michael J. Fox Foundation since 2011 to identify and optimize a-synuclein imaging agents, and are delighted that the progress supports an extension to this collaboration,” said Dr Chris Newton, Managing Director, BioFocus.
Dr Newton continued, “The program will utilize BioFocus' leading biology and chemistry platforms, and will capitalize on the company’s highly experienced teams and state-of-the-art technologies.”